| Objective:To study the effect of sanhuang capsules with captopril in rats with type 2 diabetes and treatment of the role of chronic complications and to explore its mechanism.Methods: SD rats from 100, adaptive feeding after one week, for 10 randomly selected control group, and the remaining rats with high-fat high-sugar diet for two months, and then given 40mg·kg-1 STZ injection, 1 week after the first test rat blood pressure, blood test after blood glucose, blood lipids, blood insulin, and calculated insulin sensitivity index (ISI), a fasting blood glucose greater than 7.0mmol/L with insulin sensitivity and reduce the success of those established as type 2 diabetes in rats model; Mode will become the rats were randomly divided into model group, captopril 50mg·kg-1·d-1 group, Sanhuang capsule 200mg·kg-1·d-1 group, captopril50mg·kg-1·d-1combined with Sanhuang capsule 200mg·kg-1·d-1 group, captopril plus san plus metformin Capsules 200mg·kg-1·d-1 group, metformin 200mg·kg-1·d-1; the drug administration in rats administered 1 time per day, and the model group were fed with normal saline, such as capacity, continuous use of animals were sacrificed after 4 weeks, testing blood glucose, blood lipids, blood insulin, check renal , vascular tissue for disease solutions, evaluation Sanhuang capsule combined with captopril in rats with type 2 diabetes on the vascular complications of treatment; serum CRP, TNF-α, IL-6, SOD, MDA, AGEs, AR, the initial to explore its therapeutic mechanism.Results:(1)Model to determine: Model FBG from rats in control group 6.05±0.52 mmol/l increase to 13.60±6.43 mmol/l (p<0.01), ISI serum from the control group -3.58±0.23 down to -6.05±0.37 (p<0.01),TC from the control group 1.79±0.35mmol/l increase to 3.43±1.63mmol / l (p<0.01),TG from the control group 0.85±0.21 mmol/l increase to 1.55±0.28 mmol/l (p <0.01), No significant change in blood pressure; (2) Treatment of the role:sanhuang capsule combined with captopril in rats FBG by the model group 13.60±6.43 mmol/l decreased to 9.25±2.55mmol/l (p<0.05),TC by the model group 3.43±1.63 mmol/l decreased to 1.88±0.73mmol/l (p<0.05), TGby the model group 1.55±0.28 mmol/l decreased to 1.01±0.22 mmol/l (p<0.05);captopril add sanhuang capsules add metformin group FBG by the model group rats 13.60±6.43 mmol/l decreased to 6.13±1.03 mmol/l (p<0.01),TC by the model group 3.43±1.63 mmol/l decreased to 1.71±1.03 mmol/l (p<0.05),TG by the model group 1.55±0.28 mmol/l decreased to 0.97±0.33 mmol/l (p<0.01). Sanhuang Capsule add captopril ISI serum model group from -6.05±0.37 increased to -4.80±0.53 (p<0.05), captopril add Sanhuang capsule add metformin serum ISI by model group -6.05±0.37 increased to -4.05±0.72 (p <0.01); The control group rat glomerular, tubular and interstitial changes in non-pathological. Model group, glomerular hypertrophy, increased renal tubular epithelial cells, transparent cytoplasm. While the remaining rats in each group of minor pathological changes in renal tissue. Glomeruli only see a slight increase in the number of cells. (3)Mechanism:Model group TNF-α, IL-6, CRP, respectively from the control group 1.11±0.73 ng/ml, 35.55±2.32 pg/ml, 6.55±0.42μg/ml increase to 2.51±0.76 ng/ml, 70.80±6.37 pg/ml, 15.00±0.60μg/ml (p< 0.01);sanhuang capsule combined with captopril in rats TNF-α, IL-6, CRP, respectively from the model group 2.51±0.76 ng/ml, 70.80±6.37 pg/ml, 15.00±0.60μg/ml decreased to 1.37±0.52 ng/ml, 47.73±5.01 pg/ml, 7.73±0.52μg/ml (p<0.01);captopril add sanhuang capsules add metformin TNF-α, IL-6, CRP, respectively by model group 2.51±0.76 ng/ml, 70.80±6.37 pg/ml, 15.00±0.60μg/ml decreased to 1.22±0.81 ng/ml, 45.53±3.19pg/ml, 7.63±0.73μg/ml (p<0.01). Model SOD activity in serum from the control group 102.31±14.51 U/ml reduced to 63.38±10.95U/ml (p<0.01), MDA content in the control group 0.97±030 nmol/ml increase to 1.71±1.16 nmol/ml (p<0.01); sanhuang capsule combined with captopril in serum SOD activity by the model group 63.38±10.95 U/ml increased to 85.68±3.89 U/ml (p<0.05), MDA content in the model group 1.71±1.16 nmol/ml dropped to 1.28±0.51 nmol/ml (p<0.05);captopril add sanhuang capsules add metformin serum SOD activity by the model group 63.38±10.95 U/ml increased to 88.33±5.63 U/ml (p <0.05), MDA content in the model group 1.71±1.16 nmol/ml dropped to 1.15±0.72 nmol/ml. Model AGEs content in serum from the control group383.21±70.23 pg/ml increase to 701.32±79.36 pg/ml (p <0.01), AR activity from the control group 367.37±58.35 ng/ml increase to 698.37±57.38 ng/ml; sanhuang capsule combined with captopril in rats by serum AGEs content in model group 701.32±79.36 pg/ml dropped to617.53±68.65 pg/ml (p>0.05), AR activity by the model group 698.37±57.38 ng/ml dropped to 577.77±29.71ng/ml (p<0.05); captopril add add sanhuang capsules metformin serum AGEs concentration from the model group 701.32±79.36pg/ml dropped to588.89±48.78pg/ml (p <0.05), AR activity by the model group 698.37±57.38ng/ml dropped to 536.65±53.75 ng/ml (p<0.05 ). Conclusion: (1) copy of this experimental model of type 2 diabetes is a success. (2) Sanhuang capsule combined with captopril on chronic complications of type 2 diabetes is effective in the treatment of the role: more than 3 significant improvement in a small number of symptoms, hypoglycemic, lipid-lowering, increased insulin sensitivity index, kidney, vascular protective effects . (3) its mechanism and to reduce serum CRP, TNF-α, IL-6, MDA, AGEs content, AR activity, increased SOD activity.
|
PDF Full Text Request